Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012;17(4):513-24.
doi: 10.1634/theoncologist.2012-0003. Epub 2012 Apr 3.

Bevacizumab-based Therapies in the First-Line Treatment of Metastatic Colorectal Cancer

Affiliations
Free PMC article
Review

Bevacizumab-based Therapies in the First-Line Treatment of Metastatic Colorectal Cancer

John H Strickler et al. Oncologist. .
Free PMC article

Abstract

Since its approval for the first-line treatment of metastatic colorectal cancer (mCRC), bevacizumab has become a standard treatment option in combination with chemotherapy for patients with mCRC. Bevacizumab has demonstrated efficacy in combination with a number of different backbone chemotherapy regimens, and its widespread use has introduced several important questions regarding the selection and optimization of bevacizumab-based treatment regimens, its use in various patient populations, and the identification of associated adverse events. This review discusses the results of several phase II and phase III clinical trials, as well as large observational studies, to address the use of bevacizumab in the treatment of patients with mCRC in the first-line setting.

Conflict of interest statement

Disclosures: Hebert I. Hurwitz: Roche/Genentech, Amgen, Bristol-Myers Squibb (C/A); Roche/Genentech (H); Roche/Genentech, Novartis, Bristol-Myers Squibb, Amgen, Sanofi (RF). The other author(s) indicated no financial relationships.

Figures

Figure 1.
Figure 1.
Incidence of key bevacizumab-related adverse events in selected phase III randomized clinical trials. Abbreviations: ATE, arterial thromboembolism; BV, bevacizumab; GIP, gastrointestinal perforation; HTN, hypertension; MAX, Mitomycin Avastin® Xeloda.

Similar articles

See all similar articles

Cited by 24 articles

See all "Cited by" articles

Publication types

MeSH terms

Substances

Feedback